The FDA on May 26, 2017 granted regular approval to ZYKADIA®, for patients with metastatic Non-Small Cell Lung Cancer (NSCLC), whose tumors are Anaplastic Lymphoma Kinase (ALK)-positive, as detected by an FDA-approved test. ZYKADIA® is a product of Novartis Pharmaceuticals Corp.
Other Pages – Bottom Ad
Advertisement
Subscribe
